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Introduction: Steroid-resistant nephrotic syndrome overwhelmingly progresses to end-stage renal disease. More than 30 monogenic genes have been identified to cause steroid-resistant nephrotic syndrome. We previously detected causative mutations using targeted panel sequencing in 30% of patients with steroid-resistant nephrotic syndrome. Panel sequencing has a number of limitations when compared to whole exome sequencing. We employed whole exome sequencing to detect monogenic causes of steroid-resistant nephrotic syndrome in a large international cohort of 300 families.
Methods: 335 individuals with steroid-resistant nephrotic syndrome from 300 families were recruited from 4/1998 to 6/2016. Age of onset was restricted to under 25 years of age. Exome data were evaluated for 33 known monogenic steroid-resistant nephrotic syndrome genes.
Results:
In 74/300 families (25%), we identified a causative mutation in one of 20 genes known to cause steroid-resistant nephrotic syndrome. In 11 families (3.7%), we detected a mutation in a gene that causes a phenocopy of steroid-resistant nephrotic syndrome. This is consistent with our previously published identification of mutations using a panel approach. We detected a causative mutation in a known steroid-resistant nephrotic syndrome gene in 38% of consanguineous families and in 13% of non-consanguineous families, and 48% of children with congenital nephrotic syndrome.
A total of 68 different mutations were detected in 20 of 33 steroid-resistant nephrotic syndrome genes. Fifteen of these mutations were novel. NPHS1, PLCE1, NPHS2 and SMARCAL1 were the most common genes in which we detected a mutation. In another 28% of families, we detected mutations in one or more candidate genes for steroid-resistant nephrotic syndrome.
Conclusions:
Whole exome sequencing is a sensitive approach towards diagnosis of monogenic causes of steroid-resistant nephrotic syndrome. A molecular genetic diagnosis of steroid-resistant nephrotic syndrome may have important consequences for the management of treatment and kidney transplantation in steroid-resistant nephrotic syndrome.
INTRODUCTION
Nephrotic syndrome in childhood is characterized by proteinuria (>40 mg/m 2 /hour), hypoalbuminemia, edema and hyperlipidemia. It can cause hypertension, severe infections and thrombotic events. Patients are classified by their response to steroid therapy. In children and young adults, about 80% of patients respond to standard steroid therapy and are termed steroid sensitive (1) . In contrast, individuals with steroid-resistant nephrotic syndrome overwhelmingly progress to chronic kidney disease (CKD) and end-stage renal disease (ESRD). At this time, there is no effective therapy to curtail the relentless progression to ESRD.
The most frequent kidney histologic feature of steroid-resistant nephrotic syndrome is focal segmental glomerulosclerosis (FSGS). In patients with FSGS, the risk of recurrence after kidney transplantation is estimated to be ~33% (2-4). FSGS constitutes the third most prevalent cause of ESRD in the first 2 decades of life (5). To date, more than 30 monogenic causes of steroidresistant nephrotic syndrome have been identified (6), many of which implicate the glomerular podocyte and slit membrane as the primary sites where the pathogenesis of steroid-resistant nephrotic syndrome unfolds (7). The majority of genes known to cause steroid-resistant nephrotic syndrome are recessively inherited. Patients with mutations in these genes manifest with steroid-resistant nephrotic syndrome in childhood and adolescence, whereas dominant steroid-resistant nephrotic syndrome genes often manifest later in life.
We showed previously by targeted panel sequencing of 27 known steroid-resistant nephrotic syndrome genes that in 30% of steroid-resistant nephrotic syndrome cases with onset before 25 years, a causative mutation can be detected (8). However, panel sequencing by multiplex polymerase chain reaction (PCR) is limited by requiring large numbers of Sanger sequencing to confirm individual genetic variants (8). Additionally, evaluation of genes by panel sequencing is limited to approximately 30 genes. With the growing number of genes available, we sought a mechanism by which we could evaluate a patient for a high number of steroid-resistant nephrotic syndrome genes, as well as detect novel causes of nephrosis should no known gene be identified.
In a cohort of patients with CKD and the phenotype of increased kidney echogenicity, we identified a causative mutation in 63% using whole exome sequencing (9). We evaluated here the utility of whole exome sequencing in an international cohort with steroid-resistant nephrotic syndrome. To date, this cohort is the largest to undergo whole exome sequencing (10). Given the very high rate of establishing an etiologic diagnosis and the significant implications for clinical management, pre-transplant and post-transplant care, whole exome sequencing should be considered in all individuals with steroid-resistant nephrotic syndrome diagnosed before age 25 years.
MATERIALS AND METHODS
Human subjects. The study was approved by the institutional review board of the University of Table 1 ). 335 individuals from 300 families were enrolled. Prior to December 2013, enrolled individuals were screened for mutations in WT1 and NPHS2. Those that screened positive were not included in this study.
Whole exome sequencing and variant calling. Whole exome sequencing and variant burden analysis were performed as previously described (11-13). Genomic DNA was isolated from blood lymphocyte or saliva samples and subjected to exome capture using Agilent SureSelect™ human exome capture arrays (Life technologies™) followed by next generation sequencing on the Illumina HighSeq™ sequencing platform. Sequence reads were mapped to the human reference genome assembly (NCBI build 37/hg19) using CLC Genomics Workbench™ (version 6.5.2) software (CLC bio, Aarhus, Denmark). Following alignment to the human reference genome (GRCh37/hg19), variants were filtered for most likely non-deleterious variants as previously described (8, 11) . Variants with minor allele frequencies >1% in the dbSNP (version 142) or in the 1,000 Genomes Project (1,094 subjects of various ethnicities; May, 2011 data release) databases were excluded as they were unlikely to be deleterious. We used manual inspection for the p.Arg229Gln mutation in the NPHS2 gene which is reported to be deleterious with other variants, which would be filtered out using this method (14). Synonymous variants and intronic variants that were not located within splice site regions were excluded. Remaining variants included non-synonymous variants and splice site variants.
Mutation calling in known SRNS genes.
We evaluated whole exome sequencing data for causative mutations in 33 steroid-resistant nephrotic syndrome genes known at the time (Supplementary Table 2 ). Mutation calling was applied as stated above, followed by filtering remaining variants for changes in the regions of the 33 genes. Remaining variants were ranked based on their probable impact on the function of the encoded protein considering evolutionary conservation among orthologues using ENSEMBL Genome Browser and assembled using Clustal Omega, as well as PolyPhen-2 (15), SIFT (16), and MutationTaster (17). Mutations were designated as likely pathogenic based on criteria given by Supplementary Table 3. Mutation calling was performed by clinician scientists/geneticists, with knowledge of the clinical phenotypes and pedigree structure, as well as experience with homozygosity mapping and whole exome sequencing evaluation. Remaining variants were confirmed in patient DNA by Sanger sequencing as previously described (8). Whenever parental DNA was available, segregation analysis was performed.
If no causative mutation was identified, we evaluated for mutations in genes that may represent phenocopies of steroid-resistant nephrotic syndrome (Supplementary Table 2 ). Variants were evaluated as above. Correlation of genotype and phenotype was examined and, if matching, the genetic variant was deemed a causative mutation.
Mutation calling to identify novel causes of steroid-resistant nephrotic syndrome.
If no causative mutation was found in a known steroid-resistant nephrotic syndrome gene and a family had homozygosity (>100Mbp) detected following homozygosity mapping, we then evaluated whole exome sequencing data for homozygous variants. Single heterozygous variants were excluded. We applied homozygosity mapping in consanguineous families or linkage analysis in sibling cases to filter variants (18). Remaining variants were ranked as described above. Variants were confirmed as described above.
Homozygosity mapping and linkage analysis. Prior to 2014, for genome-wide homozygosity mapping, the GeneChip® Human Mapping 250k d Array (Affymetrix) was used. Alternatively, homozygosity mapping data was generated from whole exome sequencing data. Nonparametric logarithm (base 10) of odds (LOD) scores were calculated using a modified version of the program GENEHUNTER2. 1 (19, 20) through stepwise use of a sliding window with sets of 110 SNPs and the program ALLEGRO (21) in order to identify regions of homozygosity as described (18, 22) using a disease allele frequency of 0.0001 and Caucasian marker allele frequencies. To generate homozygosity mapping after 2014, downstream processing of aligned BAM files was done using Picard and SAMtools4 (23). Single nucleotide variants calling was performed using Genome Analysis Tool Kit (GATK) (24) and the generated VCF file was subsequently used in Homozygosity Mapper (25). Whole exome sequencing was performed in 335 individuals from 300 families and evaluated for 4 mutations in the 33 steroid-resistant nephrotic syndrome genes known at the time (Table 1 ). In 74 5 families (25%), a causative mutation in one of 20 known steroid-resistant nephrotic syndrome genes 6 was detected (Figure 1 , Table 1 ). NPHS1 (13 families), PLCE1 (11 families), NPHS2 (8 families), 7
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and SMARCAL1 (8 families) were the most common genes in which mutations were identified, 8 comprising 51% of all mutations identified ( Figure 1 , Table 1 ). 9 10 94 of the 300 families studied by whole exome sequencing have been previously studied using 11
Fluidigm panel sequencing. The overlap between cohorts is given in Supplementary Table 4. We 12 found that whereas in 20/74 (27%) families the causative mutation was previously detected using 13 panel sequencing, 9/74 (12%) had a diagnosis made by whole exome sequencing and not by panel 14
sequencing. In an additional 28% of families, we detected a likely causative mutation in one or more 15 potential novel SRNS genes (Figure 1 ), given in Supplementary Table 5 . 16
Novel mutations detected in known steroid-resistant nephrotic syndrome genes 18
We detected 68 different mutations in 20 of 33 known steroid-resistant nephrotic syndrome genes, 53 19 of which had previously been reported in the literature (Table 1) . 15 novel mutations have not been 20 reported previously (Table 1 ). Individual families in whom a causative mutation was detected are 21 described in Supplementary Table 9 . 22
Whole exome sequencing identifies phenocopies in 11 of 90 families with a causative 24
mutation detected 25
We detected a causative mutation in 11 of 300 families with steroid-resistant nephrotic syndrome 26 (3.7%) (Figure 1, Table 1 ). Mutations were found in 8 phenocopy genes, specifically COL4A5, 27 COL4A3, CLCN5, GLA, AGXT, CTNS, FN1 and WDR19. A total of 10 different mutations were 28 detected, 5 of which are novel (Table 1) . 29
30
Novel candidate genes are identified using whole exome sequencing 31
In 61/146 (42%) consanguineous families with no causative mutation found in a known steroid-32 resistant nephrotic syndrome gene, one or more candidate genes were detected using homozygosity 33 mapping (Figure 2, Supplementary Table 5 ). In non-consanguineous families >1 individual affected, 34 linkage analysis was used to identify a potentially causative mutation in 18 of 135 families (13%). 35
36
Description of cohort 37
Onset of illness ranged from birth to 24 years of age ( Figure 3A and Supplementary Table 6 ). The 38 median age in individuals in whom a causative mutation was detected in a steroid-resistant nephrotic 39 syndrome gene was 1.7 years versus 4 years in those without a causative mutation identified, which 40 was statistically significant ( Figure 3B) . 41 42 146/300 (49%) of families were consanguineous, 56 (38%) of whom we detected a causative 43 mutation in a steroid-resistant nephrotic syndrome gene (Figure 4, Supplementary Table 7) . In 44 56/147 of families with >100 Mbp of homozygosity on mapping (38%), a causative mutation was 45 detected in a steroid-resistant nephrotic syndrome gene. In contrast, in 17/135 (13%) of non-46 consanguineous families and 18/153 (12%) of families with <100 Mbp of homozygosity (non-47 homozygous) on mapping, a causative mutation was detected in a steroid-resistant nephrotic 48 syndrome gene (Figure 4) . The difference in mutation detection between consanguineous and non-49 consanguineous families and between homozygous and non-homozygous families was statistically 50 significant using a chi-squared test (p<0.001) (Figure 4 ). There was no significant difference in the 51 rate of mutation detection when comparing families with 1 affected individual versus 2 affected 52 individuals or ≥ 3 affected individuals (Figure 4) . 53
54
In 24% of those with additional systemic manifestations in addition to kidney disease, a causative 55 mutation was detected in an steroid-resistant nephrotic syndrome gene, compared to 27% of those 56 with no extra-renal manifestations with a causative mutation detected in a steroid-resistant nephrotic 57 syndrome gene (Supplemental Figure 2 , Supplemental Table 8 ). This difference was not statistically 58
significant. 59 60
The most common clinical diagnosis was steroid-resistant nephrotic syndrome in 205/300 (68%) 61 
Summary and impact of this work 72
To date, this is the largest international cohort in which molecular causes of steroid-resistant 73 nephrotic syndrome were evaluated using whole exome sequencing. Our rate of mutation detection 74 is 25%, consistent with our previous work (8). Recently, in 187 individuals, a causative mutation was 75 detected in one of 53 steroid-resistant nephrotic syndrome genes in 26% of individuals (10). 76
We detected causative mutations in 20 of 33 known causes of steroid-resistant nephrotic syndrome, 77 with a total of 68 different mutations, 15 of which have not been reported in the literature. To 78 determine the pathogenicity of novel mutations in genes previously described to cause steroid-79 resistant nephrotic syndrome, we used a strict set of criteria separately for recessive or dominant. 80
Criteria were based on evolutionary conservation, bioinformatic prediction programs of pathogenicity, 81 and allele frequency in healthy control populations (Supplementary Table 3 and 9) . 82
83
Prior to 2014, our lab screened for mutations in NPHS2 and WT1, which may account for lower 84 prevalence in our cohort. NPHS2 and WT1, two of the three most commonly mutated genes in early-85 onset steroid-resistant nephrotic syndrome are underrepresented in the presented work, being 86 together responsible for only 3.3% (Table 1 ) of 300 cases, while they were previously reported to be 87 responsible for 15% of cases in 1783 cases (8). When all 1989 families studied in Sadowski, et al and 88 in this study, are combined together, mutation rates for NPHS2 and WT1 become more 89 representative of what has been previously published. NPHS2 has a detection rate of 9.3% 90 (185/1989) and WT1 has a detection rate of 4.4% (87/1989). Mutation rates for NPHS2 were 91 previously 9.9% and for WT1 were 4.8%. 92
93
We detected mutations in 8 genes that are phenocopies for steroid-resistant nephrotic syndrome, with 94 5 novel mutations and 5 mutations previously reported in the literature. As these genes may be 95 excluded from panels that target steroid-resistant nephrotic syndrome specifically, these families may 96
have been left without a molecular diagnosis. 97
Whole exome sequencing allows for the identification of novel genes using homozygosity mapping in 99 consanguineous families and linkage analysis in related individuals. Panels are limited as to how 100 many genes could be evaluated in a given experiment. However, whole exome sequencing allows 101 for the evaluation of all genes, including those that may phenocopy steroid-resistant nephrotic 102 syndrome and provide the opportunity for novel gene discovery.
104
Therapeutic implications
105
Identification of a monogenic cause of steroid-resistant nephrotic syndrome has significant 106 therapeutic implications. i) In children, treatment often requires prolonged steroid exposure and 107 potentially exposure to multiple immunosuppressant medications. All of these medications carry 108 significant side effect profiles, including growth failure (steroids), bone marrow suppression 109 (mycophenolate mofetil, tacrolimus, azathioprine), kidney dysfunction (tacrolimus), and unacceptable 110 cosmetic effects (cyclosporine), amongst other side effects. This generates an indication for fast, 111 efficient exome sequencing in order to avoid unfavorable side effects may be experienced while 112 taking medications that may not provide clinical benefit. ii) Identification of a causative mutation may 113 reveal that a potential therapy is available for some rare single-gene causes of nephrosis. For 114 example, if a mutation in a gene of coenzyme Q10 biosynthesis (COQ2, COQ6, ADCK4, or PDSS2) is 115 detected, treatment with coenzyme Q10 may be indicated (26-28). In the case of the individual with 116 COQ2 mutation, this individual was placed on COQ10 therapy and experienced a sustained 117 remission of nephrosis. iii) Identification of causative mutations in WT1 can also lead to surgical 118 evaluation and intervention to remove streak gonads with potential for malignant transformation (29). 119 iv) Genotype and phenotype correlations in the future may lead to stratification in clinical trials for 120 novel therapeutics. In our study, we identify 5 families with the p.R1160* mutation in NPHS1. This 121 mutation has been shown to cause congenital nephrotic syndrome; however, in some patients with 122 this mutation, a milder phenotype has been reported (30 Table 1 : Number and proportion of 300 families with steroid-resistant nephrotic syndrome, in whom causative mutations in one of 23 known monogenic causes of steroid-resistant nephrotic syndrome were detected. 54 of the mutations detected have previously been reported in BioBase, and 20 are novel (respective genes shown on a blue background). The most common genes to have a mutation detected in steroid-resistant nephrotic syndrome families were NPHS1, PLCE1, NPHS2, and SMARCAL1 (51% of all steroid-resistant nephrotic syndrome gene mutations detected). In an additional 11 families, mutations were detected in 8 genes that cause a kidney disease that is a phenocopy of steroid-resistant nephrotic syndrome (respective genes shown on an orange background). Five of the mutations identified have previously been reported in BioBase, and 5 are novel.
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